Seer, Inc. (SEER) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Seer, Inc. (SEER) Healthcare & Pipeline Overview

Seer, Inc. specializes in proteomics, offering its Proteograph Product Suite to researchers in therapeutic and diagnostic research, positioning itself as a key player in the life sciences sector with a focus on innovation and collaboration.

What Is the Investment Thesis for SEER?

Seer, Inc. presents a unique investment thesis driven by its innovative Proteograph Product Suite, which addresses a significant gap in proteomic research. The company's gross margin stands at 51.1%, indicating a strong potential for profitability as it scales. With a market capitalization of $111M and a focus on expanding its customer base across academic and biopharmaceutical sectors, Seer is positioned for growth. Key growth catalysts include ongoing collaborations, increasing demand for proteomic research tools, and advancements in automation technology. However, the company faces risks such as its negative profit margin of -444.0%, which may affect its ability to sustain operations without additional funding. Investors may want to evaluate these factors as they evaluate Seer's potential for future growth.

Based on FMP financials and quantitative analysis

SEER Key Highlights

Market capitalization of $111M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 51.1% indicates a strong potential for profitability as the company scales its operations.
• Employee count of 134 highlights Seer's commitment to innovation and growth in the life sciences industry.
• Negative profit margin of -444.0% signals challenges in achieving profitability, necessitating careful financial management.
• Beta of 1.60 suggests higher volatility compared to the market, indicating potential risks for investors.

Who Are SEER's Competitors?

SEER is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SEER's Key Strengths?

Innovative product offerings that address critical needs in proteomic research.

• Strong partnerships with reputable research institutions enhance credibility.
• High gross margin indicates potential for profitability as the business scales.

What Are SEER's Weaknesses?

Negative profit margin raises concerns about financial sustainability.

• Limited brand recognition compared to established competitors in the biotechnology sector.
• Relatively small workforce may limit operational capacity and growth.

What Could Drive SEER Stock Higher?

Expansion of collaborations with academic institutions to enhance product development.

• Continuous improvement and updates to the Proteograph Product Suite to meet market demands.
• Launch of new marketing initiatives aimed at increasing brand awareness and customer acquisition.
• Participation in industry conferences and events to showcase innovations and network with potential partners.

What Are the Key Risks for SEER?

Financial-distress signal — its Altman Z-Score of -0.68 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-26.6%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Dependence on external funding for research and development activities.
• Competition from established biotechnology firms may impact market share.
• Regulatory hurdles that could delay product approvals and commercialization.
• Economic fluctuations affecting research budgets and funding in the biotechnology sector.

What Are the Growth Opportunities for SEER?

• Growth opportunity 1: The global proteomics market is projected to grow significantly, reaching $46.9 billion by 2026. Seer, Inc.'s Proteograph Product Suite is uniquely positioned to capture market share by providing comprehensive solutions that streamline proteomic research, thereby enhancing its competitive advantage.
• Growth opportunity 2: As biopharmaceutical companies increasingly invest in personalized medicine, the demand for advanced proteomic tools is expected to rise. Seer's focus on developing innovative products tailored for therapeutic research aligns with this trend, potentially leading to increased sales and market penetration.
• Growth opportunity 3: Collaborations with leading research institutions, such as the Salk Institute, enhance Seer's credibility and expand its reach in the academic sector. These partnerships can lead to new product development and increased adoption of Seer's technologies, driving future revenue growth.
• Growth opportunity 4: The integration of automation in proteomic workflows is becoming a key trend in the industry. Seer's automation instrumentation within its Proteograph Product Suite positions the company to capitalize on this trend, making proteomic studies more efficient and accessible for researchers.
• Growth opportunity 5: The rise of clinical trials focusing on proteomic biomarkers presents an opportunity for Seer to expand its market presence. By aligning its product offerings with the needs of clinical researchers, Seer can tap into new revenue streams and enhance its growth trajectory.

What Threats Does SEER Face?

• Intense competition from established players and emerging startups in the biotechnology space.
• Potential regulatory challenges affecting product development and commercialization.
• Market volatility and economic downturns impacting research funding and investments.

What Are SEER's Competitive Advantages?

• Innovative Proteograph Product Suite that integrates multiple components for proteomic studies.
• Strong collaborations with leading research institutions enhance credibility and market reach.
• Focus on automation technology differentiates Seer from competitors.
• Expertise in proteomics positions the company as a thought leader in the industry.
• Commitment to research and development fosters continuous innovation.

What Does SEER Do?

Founded in 2017 and headquartered in Redwood City, California, Seer, Inc. is a pioneering life sciences company dedicated to decoding the proteome, the entire set of proteins expressed by an organism. Originally named Seer Biosciences, Inc., the company rebranded in July 2018 to reflect its broader mission. Seer has developed the Proteograph Product Suite, an integrated solution that includes consumables, automation instrumentation, and software designed to facilitate proteomic studies. This suite is targeted at researchers in therapeutic and diagnostic research, as well as clinical trials, enabling them to conduct comprehensive proteomic analyses. Seer's products are primarily aimed at academic institutions, life sciences research laboratories, and biopharmaceutical companies, focusing on non-diagnostic and non-clinical applications. The company has established strategic collaborations with notable organizations such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies, enhancing its research capabilities and market reach. As of now, Seer employs 134 individuals, reflecting its commitment to innovation and growth in the biotechnology sector.

What Products and Services Does SEER Offer?

• Develops the Proteograph Product Suite for proteomic studies.
• Provides consumables, automation instrumentation, and software for researchers.
• Targets academic institutions, life sciences laboratories, and biopharmaceutical companies.
• Focuses on non-diagnostic and non-clinical applications.
• Engages in strategic collaborations to enhance research capabilities.
• Aims to decode the proteome for therapeutic and diagnostic research.

How Does SEER Make Money?

• Generates revenue through the sale of the Proteograph Product Suite.
• Targets research institutions and biopharmaceutical companies as primary customers.
• Focuses on consumables, instrumentation, and software solutions.
• Engages in collaborations that may provide additional funding and research opportunities.
• Plans to expand product offerings to meet evolving market demands.

What Industry Does SEER Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and personalized medicine. The proteomics market alone is expected to reach $46.9 billion by 2026, fueled by increasing investments in research and development. Seer, Inc. is well-positioned within this landscape, offering innovative solutions that cater to the growing demand for proteomic analysis in therapeutic and diagnostic applications. The competitive landscape includes established players and emerging startups, making innovation and collaboration critical for success.

Who Are SEER's Key Customers?

• Academic institutions conducting proteomic research.
• Life sciences research laboratories requiring advanced proteomic tools.
• Biopharmaceutical companies focused on therapeutic and diagnostic applications.
• Clinical researchers involved in trials utilizing proteomic analysis.
• Collaborative partners in research and development initiatives.

Seer, Inc. Financial Trajectory

Seer, Inc. (SEER) reported $3.1M in revenue for Q2 2026, reflecting 14.6% growth compared to the prior quarter. The company recorded a net loss of $16.9M, with diluted EPS of $-0.31. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SEER averaged $-0.30 in diluted EPS.

Company Profile

Seer, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Omid C. Farokhzad. SEER has traded publicly since 2020.

How Seer, Inc. Is Valued

Seer, Inc. carries a market capitalization of $111M, placing it in the micro-cap category. Relative to its peer group, SEER's quantitative score of 18/100 is below the peer average of 61/100.

Return on equity for Seer, Inc. stands at -26.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -56.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -78.2%, the inverse of the P/E and a quick read on earnings relative to price.

Seer, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.68 places it in the distress zone, a signal of elevated financial risk.

Seer, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.3% below estimates on average.

Wall Street analysts project Seer, Inc. revenue of about $16.1M for fiscal 2026, with EPS near $-1.04.

SEER Financials

SEER Latest News

SEER Analyst Consensus

SEER MoonshotScore

What Investors Ask About Seer, Inc. (SEER) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources